Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOUHR4)

Drug Name
CA-170 Drug Info
Synonyms
3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
16212596
CAS Number
CAS 103831-11-4
TTD Drug ID
DMOUHR4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting V-set immunoregulatory receptor (VSIR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
JNJ-61610588 DMSPQDM Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
CI-8993 DM2OB6S Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Avelumab DMSZLJR Merkel cell carcinoma 2C34 Approved [5]
Durvalumab DM4PVDY Urothelial carcinoma 2C92.0 Approved [6]
RG-7446 DM69XMQ Urothelial carcinoma 2C92.0 Approved [7]
Bavencio DMU9C8F Merkel cell carcinoma 2C34 Approved [8]
Atezolizumab DMMF8U0 Non-small-cell lung cancer 2C25 Approved [9]
Sugemalimab DMH5YQ3 Non-small-cell lung cancer 2C25 Approved in China [10]
KN046 DMSDBPG Non-small-cell lung cancer 2C25.Y Phase 3 [11]
MEDI4736 DM5X849 Solid tumour/cancer 2A00-2F9Z Phase 3 [12]
MPDL-3280A DM9K3LM Melanoma 2C30 Phase 3 [13]
CS1001 DMSY0NE Non-small-cell lung cancer 2C25 Phase 3 [14]
Avelumab DMSZLJR Merkel cell carcinoma 2C34 Approved [5]
Durvalumab DM4PVDY Urothelial carcinoma 2C92.0 Approved [6]
RG-7446 DM69XMQ Urothelial carcinoma 2C92.0 Approved [7]
Bavencio DMU9C8F Merkel cell carcinoma 2C34 Approved [8]
Atezolizumab DMMF8U0 Non-small-cell lung cancer 2C25 Approved [9]
Sugemalimab DMH5YQ3 Non-small-cell lung cancer 2C25 Approved in China [10]
KN046 DMSDBPG Non-small-cell lung cancer 2C25.Y Phase 3 [11]
MEDI4736 DM5X849 Solid tumour/cancer 2A00-2F9Z Phase 3 [12]
MPDL-3280A DM9K3LM Melanoma 2C30 Phase 3 [13]
CS1001 DMSY0NE Non-small-cell lung cancer 2C25 Phase 3 [14]
⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Inhibitor [1]
V-set immunoregulatory receptor (VSIR) TT51SK8 VISTA_HUMAN Inhibitor [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of Curis.
5 Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
8 ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
10 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
11 Clinical pipeline report, company report or official report of Alphamab Oncology.
12 National Cancer Institute Drug Dictionary (drug id 740856).
13 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
14 GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.